Targeted cardio-neuro Affinia Therapeutics focuses on diseases of the heart and nervous system, leveraging AAV9-based delivery and proprietary capsid engineering. This presents an opportunity to partner on preclinical-to-clinical programming, exploring collaborations with cardiology and neurology-focused biotechs or pharma with assets in these indications.

Clinical program push Lead program AFTX-201 targets BAG3-associated dilated cardiomyopathy and is advancing toward Phase 1/2 UPBEAT trials. Potential sales angle includes co-development or licensing conversations with companies seeking heart failure gene therapies or where BAG3 biology is a strategic fit.

Capital growth signals Recent $40M Series C led by NEA and ongoing fundraising indicate strong investor confidence and runway for expansion. Leverage this momentum to propose services or partnerships around manufacturing scale-up, vector production, or capacity planning for future clinical programs.

Manufacturing edge Affinia emphasizes high-yield manufacturing technology and BBB-penetrant capsids. Sales conversations can target CROs and CDMOs needing advanced GMP production capabilities, process development expertise, and scalable AAV manufacturing for broader CNS and CNS-penetrant therapies.

Leadership and culture Key hires in operations and people, plus a fast-paced, collaborations-friendly culture, signal readiness for rapid partnerships and joint ventures. Position Affinia as a collaborative development partner for peers seeking to accelerate gene therapy programs with disciplined program management.